| __timestamp | Sarepta Therapeutics, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 94103000 | 18516000 |
| Thursday, January 1, 2015 | 146194000 | 34140000 |
| Friday, January 1, 2016 | 130000 | 51872000 |
| Sunday, January 1, 2017 | 7353000 | 71772000 |
| Monday, January 1, 2018 | 34193000 | 97501000 |
| Tuesday, January 1, 2019 | 56586000 | 118590000 |
| Wednesday, January 1, 2020 | 63382000 | 169802000 |
| Friday, January 1, 2021 | 97049000 | 7491000 |
| Saturday, January 1, 2022 | 139989000 | 8799000 |
| Sunday, January 1, 2023 | 150343000 | 253598000 |
Unlocking the unknown
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. Sarepta Therapeutics, Inc. and Xencor, Inc. have shown intriguing trends in their cost of revenue from 2014 to 2023. Sarepta's cost of revenue has seen a significant increase, peaking in 2023 with a 60% rise from its 2014 figures. In contrast, Xencor's costs have fluctuated more dramatically, with a notable spike in 2023, reaching over 13 times its 2014 costs. This divergence highlights the varying strategies and market conditions faced by these companies. While Sarepta's steady growth suggests a consistent scaling of operations, Xencor's volatility may reflect strategic shifts or market challenges. Investors should consider these trends when evaluating the financial health and strategic direction of these biotech firms.
Cost of Revenue Trends: Johnson & Johnson vs Sarepta Therapeutics, Inc.
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Sarepta Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Zoetis Inc. vs Sarepta Therapeutics, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs Sarepta Therapeutics, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs Pharming Group N.V.
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Wave Life Sciences Ltd.'s Expenses
Analyzing Cost of Revenue: Sarepta Therapeutics, Inc. and Geron Corporation
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Evotec SE's Expenses